Polycythemia Vera

This is a specific type of polycythemia where your bone marrow makes too many red blood cells, white blood cells, and platelets. It's a long-term condition that can lead to blood clots, stroke, and other complications. It's not caused by anything you did, but rather by a change in your bone marrow.

Condition

What people with Polycythemia Vera report

Every report comes from a Lived member, sent anonymously.

Have you had Phlebotomy for Polycythemia Vera?

NameHow it went

About Polycythemia Vera

What It Is

Polycythemia vera (PV) is a rare, long-term blood cancer that starts in the bone marrow, the spongy tissue inside bones where blood cells are made. In PV the marrow makes too many red blood cells, and often too many white blood cells and platelets as well. The extra cells make the blood thicker than normal, so it flows more slowly and clots more easily. That tendency to clot is the main reason PV matters. Clots can block arteries or veins and cause a stroke, a heart attack, or a clot in a leg vein that travels to the lungs. Many people feel well and learn they have PV from a routine blood test. Others notice headaches, dizziness, a red or flushed face, vision changes, or itching all over the body, often after a warm bath or shower. An enlarged spleen, which stores some of the extra cells, can cause a feeling of fullness under the left ribs.

Causes & Risk Factors

PV begins when a blood-forming stem cell in the bone marrow picks up a genetic change during a person's lifetime. Nearly everyone with PV has a change in a gene called JAK2, which normally acts like a switch for blood cell production. The altered switch stays turned on, so the marrow keeps making cells the body does not need. This change is acquired, not inherited, so PV usually does not run in families, although rare family clusters exist. It is most often diagnosed around age 60 and is somewhat more common in men. No lifestyle habit is known to cause it.

How It's Diagnosed

PV is usually suspected when a blood count shows high hemoglobin (the oxygen-carrying protein in red cells) or high hematocrit (the share of blood volume made up of red cells). Current criteria treat hemoglobin above 16.5 g/dL or hematocrit above 49% in men, and above 16 g/dL or 48% in women, as high enough to raise the question. A high red cell count alone does not mean PV. Smoking, lung or heart disease, sleep apnea, testosterone treatment and some kidney tumors can all raise red cells as the body responds to low oxygen or extra hormone signals. To tell these apart, clinicians test for the JAK2 change and measure erythropoietin, the hormone that tells the marrow to make red cells. In PV the marrow is working on its own, so erythropoietin is usually low. A bone marrow biopsy is often done to confirm the diagnosis and give a baseline for later comparison.

Treatment Options

There is no standard treatment that cures PV, but treatment is effective at its main goal: preventing clots. Two measures are used for almost everyone. The first is phlebotomy, removing blood much like a blood donation, to bring the hematocrit below 45%. A large trial found that keeping hematocrit under that line cut serious clots and heart-related deaths compared with a looser target of 45 to 50%. The second is low-dose aspirin, which lowers clot risk for people who have no reason to avoid it, such as a bleeding problem. People at higher risk of clots, generally those over 60 or anyone who has already had a clot, usually also take a medicine that lowers blood cell production. Hydroxyurea is a daily capsule that has been used for decades; it requires regular blood counts and is avoided in pregnancy. Ropeginterferon alfa-2b (Besremi) is a long-acting interferon injection given every two to four weeks. It is FDA-approved for PV, and its main trade-offs are flu-like symptoms, fatigue and, less often, mood changes or autoimmune problems, which need monitoring. Ruxolitinib (Jakafi), a pill that blocks the overactive JAK signal, is approved for people whose PV is not controlled by hydroxyurea or who cannot tolerate it, and it often helps itching and spleen symptoms. Rusfertide (Mimrylo), approved in 2026, is a weekly injection that limits the iron available for making red cells. In its main trial, about 77% of people who had needed frequent phlebotomy avoided it over the study period, compared with 33% on placebo. It can raise platelet counts, so blood counts are checked often when starting it. Itching that persists can be treated in its own right, and stopping smoking and managing blood pressure and cholesterol further lower clot risk.

What to Expect

PV is a chronic condition that most people live with for many years. Median survival is about 15 years from diagnosis, and much longer for people diagnosed young, though these are population averages rather than individual predictions. Day to day, life usually revolves around regular blood counts, periodic phlebotomy and adjusting medicines to keep the hematocrit in range. Phlebotomy sessions are short, but they can leave some people tired for a day or so. Symptoms such as itching, fatigue and headaches vary a great deal and do not always track blood counts, so it helps to report them even when numbers look good. Over decades, PV can change. Some people develop myelofibrosis, in which the marrow becomes scarred and the spleen enlarges further, and a smaller number develop acute myeloid leukemia. A hematologist (a blood specialist) watches for these changes, which is why follow-up continues even when someone feels well. Surgery and pregnancy need advance planning, because both change clot and bleeding risk.

When to Seek Help

See a clinician if a blood test shows high hemoglobin or hematocrit, or if you have unexplained itching after bathing, flushing, headaches or fullness under the left ribs. If you already have PV, contact your care team right away for a swollen, painful leg, a new fullness under the left ribs, unexplained weight loss, or side effects from treatment such as low mood. Call 911 for sudden chest pain, sudden shortness of breath, or signs of a stroke such as numbness or weakness on one side, trouble speaking, trouble seeing, or a sudden severe headache. These can mean a clot, and fast treatment matters.

Questions to Ask Your Doctor

  1. 1.Am I considered low risk or high risk for clots, and how does that change my treatment?
  2. 2.What hematocrit target are we aiming for, and how often will I need blood counts or phlebotomy?
  3. 3.Would I benefit from hydroxyurea, an interferon, ruxolitinib or rusfertide, and how would we choose among them?
  4. 4.Which symptoms or blood count changes would suggest the disease is progressing?
  5. 5.How should we plan around surgery, travel or pregnancy given my clot and bleeding risk?

Last reviewed • Oct 2026

Educational content, not medical advice.